Matthew M. Yeh

Matthew M. Yeh

Auto-generated profile, based on publicly available information

Matthew M. Yeh

Department of Laboratory Medicine and Pathology, University of Washington School of Medicine, Seattle, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 June 2014 in Laboratory Investigation
Verified
Journal Article
Open access
PDF file
DDDao-Fu Dai
Dao-Fu Dai
PSPaul E Swanson
Paul E Swanson
EKEric V Krieger
Eric V Krieger
ILIris W Liou
Iris W Liou
RCRobert L Carithers
Robert L Carithers
MYMatthew M Yeh
Matthew M Yeh
Chronic right heart failure predisposes to hepatic passive congestion and centrizonal necrosis that may lead to hepatic fibrosis (cardiac sclerosis). Although there have been several studies on the histologic features of congestive hepatopathy, there is no available grading system. In this study we developed a novel grading system for congestive hepatic fibrosis. Liver biopsies were examined in patients with chronic heart failure of various etiologies including congenital heart disease, idiopathic cardiomyopathy, ischemic heart disease, and valvular heart disease. The cases with available echocardiography and/or right heart catheterization were included. Cases with other types of underlying chronic liver diseases, alcoholic liver disease, significant steatosis (>20%), malignant neoplasm, and acute heart failure or shock were excluded. After exclusion, 42 cases were included in the study. We herein proposed a novel congestive hepatic fibrosis score and correlated it with the right heart structure and function obtained by echocardiography and/or right heart catheterization. Our results showed that congestive hepatic fibrosis score is well correlated with the right atrial pressure (P for trend <0.001). The presence of portal fibrosis (congestive hepatic fibrosis scores 2 and 3) is associated with significantly higher right atrial pressure than those with no fibrosis (P<0.001) or with centrizonal fibrosis only (P=0.02). Congestive hepatic fibrosis score is also significantly associated with increasing severity of right atrial dilatation (P=0.03) and right ventricular dilatation (P=0.02), indicators for chronic volume and/or pressure overload. Other histopathologic features include sinusoidal dilatation and centrizonal hepatocyte atrophy. In summary, although sinusoidal dilatation and centrizonal fibrosis are the hallmarks of hepatic passive congestion, the presence of portal fibrosis is suggestive of more advanced disease, as it correlates with more severe impairment of right heart function, regardless of the etiologies of right heart failure. Congestive hepatic fibrosis score is a useful indicator of clinical severity.

1 November 2019 in Seminars in Diagnostic Pathology
Verified
Journal Article
Closed access
YZYoh Zen
Yoh Zen
MYMatthew M. Yeh
Matthew M. Yeh

1 November 2015 in Human Pathology
Verified
Journal Article
Closed access
MYMatthew M. Yeh
Matthew M. Yeh
YLYajuan Liu
Yajuan Liu
MTMichael Torbenson
Michael Torbenson

1 December 2018 in Annals of Diagnostic Pathology
Verified
Journal Article
Closed access
LKLisa K. Koch
Lisa K. Koch
MYMatthew M. Yeh
Matthew M. Yeh

1 January 2021 in Journal of the Formosan Medical Association
Verified
Journal Article
Open access
YCYen-Ying Chen
Yen-Ying Chen
MYMatthew M. Yeh
Matthew M. Yeh
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in North America and Europe, with increasing prevalence in other regions of the world. Its spectrum encompass steatosis, non-alcoholic steatohepatitis (NASH), fibrosis and cirrhosis. It is considered as the manifestation of metabolic syndrome in liver, and its development and progression is influenced by complex interaction of environmental and genetic factors. In this review we discuss the histopathological features, differential diagnoses, and the commonly used grading and staging systems of NAFLD. NAFLD associated with other diseases, histological changes after therapeutic intervention and recurrence or occurrence of NAFLD after liver transplantation are also addressed.

1 November 2017 in Human Pathology
Verified
Journal Article
Closed access
DBDustin E. Bosch
Dustin E. Bosch
MYMatthew M. Yeh
Matthew M. Yeh